Cis‐dichlorodiammineplatinum (II) and VP 16–213 combination chemotherapy for non‐small cell lung cancer

Abstract

Twenty‐three patients with non‐small cell lung cancer were treated with a combination of cis‐dichlorodiammineplatinum(II) 100 mg/m² IV on day 1 and VP 16–213 80 mg/m² IV on days 1–3. Eighteen patients are evaluable for response. Seven partial remissions with a median duration of 3 months (range, 1–13+) have been observed. Three patients exhibit stable disease, and eight patients show tumor progression. Overall survival was 5+ months (range, 1–13+); 7.5 months (range, 3–13+) for responders and 3+ months (range, 1–9+) for non‐responders. Hematologic toxicity was acceptable, but poor subjective tolerance (nausea, vomiting, loss of appetite) was the main factor limiting treatment duration.